查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1611207

腫瘤壞死因子（TNF）抑制劑的全球市場規模、佔有率和趨勢分析報告：按產品、應用、銷售管道、地區和細分市場預測（2025-2030）

Tumor Necrosis Factor Inhibitor Drugs Market Size, Share & Trends Analysis Report By Product (Humira, Enbrel Remicade, Simponi/Simponi Aria, Cimzia), By Application, By Sales Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

腫瘤壞死因子 (TNF) 抑制劑市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球腫瘤壞死因子（TNF）抑制劑市場規模將達到266億美元，2025年至2030年複合年成長率為2.2%。

自體免疫疾病盛行率的增加、技術的快速進步以及全球醫療保健支出的增加是預計推動成長的一些關鍵因素。

目前市面上有五種核准的TNF 抑制劑： Humira（Adalimumab）、 Enbrel（Etanercept）、 Remicade（Infliximab）、Simponi/Simponi Aria（戈利木單抗）和Cimzia （賽妥珠單抗）。生物相似藥Humira、 Enbrel和Remicade的推出為市場帶來了重大模式轉移。

生物相似藥浪潮對生物製藥的銷售構成了重大的內部威脅，因為生物相似藥的效率與原廠藥相當。生物相似藥具有成本效益，使其成為經濟敏感地區的有吸引力的選擇。此外，印度、中國、韓國等新興國家也積極進入生物相似藥市場。

涉及TNF抑制劑治療的關鍵治療領域包括類風濕性關節炎、乾乾癬、乾癬乾癬性關節炎、克隆氏症和潰瘍性大腸炎。儘管這些藥物主要用於治療自體免疫疾病，但一些正在進行的研究正在調查 TNF 抑制劑在治療癌症和其他發炎性疾病中的作用。

TNF抑制劑領域的一些主要公司參與了併購和合資企業聯合產品開發等策略性措施。此外，廠商之間的專利侵權問題也加劇了市場競爭。例如，艾伯維 (AbbVie) 與勃林格殷格翰 (Boehringer Ingelheim) 解決了有關修美樂 (Humira ) 的智慧財產權 (IP) 問題。根據該協議，勃林格殷格翰獲得了Humira在美國的智慧財產權非獨家許可。

腫瘤壞死因子 (TNF) 抑制劑市場報告亮點

  • 從產品來看，Humira）在2024年以40.5%的最大銷售佔有率佔據市場主導地位，因為它已證明其對多種自體免疫疾病的有效性，並在患者和醫療保健專業人員中建立了牢固的信任。
  • 2024年，類風濕性關節炎因其在全球範圍內的高盛行率而佔據市場主導地位，佔據最大的收益佔有率，達到17.51%。
  • 由於易於存取數位平台、順利訂購、準時交貨和實惠的價格，線上藥局預計在預測期內將以最高的複合年成長率成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章腫瘤壞死因子 (TNF) 抑制劑市場變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 腫瘤壞死因子（TNF）抑制劑市場分析工具
    • 波特的分析
    • PESTEL分析

第4章腫瘤壞死因子（TNF）抑制劑市場：產品估算與趨勢分析

  • 產品市場佔有率（2024/2030）
  • 產品細分儀表板
  • 按產品分類的市場規模、預測和趨勢分析（2018-2030）
  • Humira
  • Enbrel
  • Remicade
  • Simponi/Simponi Aria
  • Cimzia
  • 生物相似藥

第5章腫瘤壞死因子（TNF）抑制劑市場：應用預估及趨勢分析

  • 應用市場佔有率（2024/2030）
  • 使用細分儀表板
  • 按應用分類的市場規模、預測和趨勢分析（2018-2030）
  • 類風濕性關節炎
  • 乾癬
  • 乾癬性關節炎
  • 克隆氏症
  • 潰瘍性大腸炎
  • 潰瘍性大腸炎：市場收益估計與預測（2018-2030）
  • 僵直性脊椎炎
  • 幼年特發性關節炎
  • 化膿性汗腺炎
  • 其他

第6章腫瘤壞死因子（TNF）抑制劑市場：銷售管道估算及趨勢分析

  • 銷售管道市場佔有率（2024/2030）
  • 銷售管道細分儀表板
  • 按銷售管道分類的市場規模、預測和趨勢分析（2018-2030）
  • 醫院藥房
  • 專業藥房
  • 網路藥房

第7章腫瘤壞死因子（TNF）抑制劑市場：區域估計和趨勢分析

  • 區域市場佔有率分析（2024/2030）
  • 區域市場儀表板
  • 市場規模及預測趨勢分析（2018-2030）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第8章 競爭格局

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/上市公司
    • AbbVie, Inc.
    • Amgen, Inc.
    • Johnson &Johnson Services, Inc.
    • UCB SA
    • Pfizer, Inc.
    • Novartis International AG
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Merck &Co., Inc.
Product Code: GVR-3-68038-150-4

Tumor Necrosis Factor Inhibitor Drugs Market Growth & Trends:

The global tumor necrosis factor inhibitor drugs market size is estimated to reach USD 26.6 billion by 2030, registering a CAGR of 2.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of autoimmune diseases, rapid technological advancements, and rise in healthcare expenditure across the globe are some of the major factors expected to drive the growth.

Currently, there are five approved TNF inhibitor drugs in the market- Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Simponi/Simponi Aria (golimumab), and Cimzia (certolizumab). Biosimilar versions of Humira, Enbrel, and Remicade have been launched, causing a significant paradigm shift in the market.

The wave of biosimilars pose a significant internal threat to the biologics sale as biosimilars have a comparable efficiency as the original products. The cost-effectiveness of biosimilars makes them an attractive choice in economically sensitive areas. In addition, emerging countries, such as India, China, and South Korea are active participants in the biosimilar market.

Some of the key therapeutic areas involving treatment with TNF inhibitor drugs are rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Although these medicines are mostly used for the treatment of autoimmune diseases, several ongoing studies are investigating the role of TNF inhibitors in the treatment of cancer and other inflammatory conditions.

Some of the key players in the TNF inhibitor space are involved in strategic initiatives, such as mergers and acquisitions and joint ventures for the co-development of products. In addition, patent infringement issues between the manufacturers makes the market dynamics intensely competitive. For instance, AbbVie resolved an issue with Boehringer Ingelheim, regarding Humira's intellectual property (IP) rights. As per the terms of the agreement, Boehringer Ingelheim received a non-exclusive license to Humira's IP in the U.S.- scheduled to begin in July 2023.

Tumor Necrosis Factor Inhibitor Drugs Market Report Highlights:

  • By product, the humira segment dominating the market with the largest revenue share of 40.5% in 2024, due to its proven effectiveness in treating various autoimmune disorders, which fostered strong trust among patients and healthcare providers.
  • In 2024, Rheumatoid arthritis dominated the market and accounted for the largest revenue share of 17.51%, due to its high prevalence globally.
  • The online pharmacy is expected to grow at the highest CAGR over the forecasted period, due to easy access to digital platforms, smooth ordering, in time delivery, and affordable pricing.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Tumor Necrosis Factor Inhibitor Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Tumor Necrosis Factor Inhibitor Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Tumor Necrosis Factor Inhibitor Drugs Market: Product Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Humira
    • 4.4.1. Humira Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Enbrel
    • 4.5.1. Enbrel Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Remicade
    • 4.6.1 Remicade Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Simponi/Simponi Aria
    • 4.7.1 Simponi/Simponi Aria Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Cimzia
    • 4.8.1 Cimzia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Biosimilars
    • 4.9.1 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Tumor Necrosis Factor Inhibitor Drugs Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Rheumatoid Arthritis
    • 5.4.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Psoriasis
    • 5.5.1. Psoriasis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Psoriatic Arthritis
    • 5.6.1. Psoriatic Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Crohn's Disease
    • 5.7.1. Crohn's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Ulcerative Colitis
  • 5.9. Ulcerative Colitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) Psoriatic Arthritis
  • 5.10. Ankylosing Spondylitis
    • 5.10.1. Ankylosing Spondylitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.11. Juvenile Idiopathic Arthritis
    • 5.11.1. Juvenile Idiopathic Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.12. Hidradenitis suppurativa
    • 5.12.1. Hidradenitis suppurativa Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.13. Others
    • 5.13.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Tumor Necrosis Factor Inhibitor Drugs Market: Sales Channel Estimates & Trend Analysis

  • 6.1. Sales Channel Market Share, 2024 & 2030
  • 6.2. Sales Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Speciality Pharmacy
    • 6.5.1. Speciality Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacy
    • 6.6.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Tumor Necrosis Factor Inhibitor Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Denmark Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Sweden Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Norway Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. China Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Japan
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. Japan Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. AbbVie, Inc.
      • 8.5.1.1. Participant's Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Recent Developments/ Strategic Initiatives
    • 8.5.2. Amgen, Inc.
      • 8.5.2.1. Participant's Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Recent Developments/ Strategic Initiatives
    • 8.5.3. Johnson & Johnson Services, Inc.
      • 8.5.3.1. Participant's Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Recent Developments/ Strategic Initiatives
    • 8.5.4. UCB S.A.
      • 8.5.4.1. Participant's Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Recent Developments/ Strategic Initiatives
    • 8.5.5. Pfizer, Inc.
      • 8.5.5.1. Participant's Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Recent Developments/ Strategic Initiatives
    • 8.5.6. Novartis International AG
      • 8.5.6.1. Participant's Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Recent Developments/ Strategic Initiatives
    • 8.5.7. Boehringer Ingelheim Pharmaceuticals, Inc.
      • 8.5.7.1. Participant's Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Recent Developments/ Strategic Initiatives
    • 8.5.8. Merck & Co., Inc.
      • 8.5.8.1. Participant's Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Tumor Necrosis Factor Inhibitor Drugs Market , by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Tumor Necrosis Factor Inhibitor Drugs Market , by Product, 2018 - 2030 (USD Million)
  • Table 5 Global Tumor Necrosis Factor Inhibitor Drugs Market , by Application, 2018 - 2030 (USD Million)
  • Table 6 Global Tumor Necrosis Factor Inhibitor Drugs Market , by Sales Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Tumor Necrosis Factor Inhibitor Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 9 North America Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 10 North America Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 12 U.S. Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 13 U.S. Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 15 Canada Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 16 Canada Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 17 Europe Tumor Necrosis Factor Inhibitor Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 18 Europe Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 19 Europe Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 20 Europe Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 21 UK Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 22 UK Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 23 UK Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 24 Germany Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 25 Germany Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 26 Germany Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 27 France Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 28 France Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 29 France Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 30 Italy Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 31 Italy Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 32 Italy Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 33 Spain Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 34 Spain Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 35 Spain Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 37 Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 38 Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 40 Japan Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 41 Japan Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 42 Japan Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 43 China Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 44 China Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 45 China Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 46 Latin America Tumor Necrosis Factor Inhibitor Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 47 Latin America Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 48 Latin America Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 49 Latin America Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 50 Brazil Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 51 Brazil Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 52 Brazil Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 53 Argentina Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 54 Argentina Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 55 Argentina Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 59 Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 60 South Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 61 South Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 62 South Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Tumor necrosis factor inhibitor drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Tumor Necrosis Factor Inhibitor Drugs Market dynamics
  • Fig. 12 Tumor Necrosis Factor Inhibitor Drugs Market: Porter's five forces analysis
  • Fig. 13 Tumor Necrosis Factor Inhibitor Drugs Market: PESTLE analysis
  • Fig. 14 Tumor Necrosis Factor Inhibitor Drugs Market: Type segment dashboard
  • Fig. 15 Tumor Necrosis Factor Inhibitor Drugs Market: Product market share analysis, 2024 & 2030
  • Fig. 16 Enbrel Market, 2018 - 2030 (USD Million)
  • Fig. 17 Remicade Market, 2018 - 2030 (USD Million)
  • Fig. 18 Simponi/Simponi Aria Market 2018 - 2030 (USD Million)
  • Fig. 19 Cimzia 2018 - 2030 (USD Million)
  • Fig. 20 Biosimilars 2018 - 2030 (USD Million)
  • Fig. 21 Simponi/Simponi Aria market, Cimzia Biosimilars 2018 - 2030 (USD Million)
  • Fig. 22 Tumor Necrosis Factor Inhibitor Drugs Market: Application segment dashboard
  • Fig. 23 Tumor Necrosis Factor Inhibitor Drugs Market: Application market share analysis, 2024 & 2030
  • Fig. 24 Rheumatoid Arthritis Market 2018 - 2030 (USD Million)
  • Fig. 25 Psoriasis Market, 2018 - 2030 (USD Million)
  • Fig. 26 Psoriatic Arthritis Market, 2018 - 2030 (USD Million)
  • Fig. 27 Ankylosing Spondylitis, 2018 - 2030 (USD Million)
  • Fig. 28 Juvenile Idiopathic Arthritis Market, 2018 - 2030 (USD Million)
  • Fig. 29 Hidradenitis suppurativa Market, 2018 - 2030 (USD Million)
  • Fig. 30 Crohn's Disease Market, 2018 - 2030 (USD Million)
  • Fig. 31 Others Market, 2018 - 2030 (USD Million)
  • Fig. 32 Tumor Necrosis Factor Inhibitor Drugs Market: Sales Channel segment dashboard
  • Fig. 33 Tumor Necrosis Factor Inhibitor Drugs Market: Sales Channel market share analysis, 2024 & 2030
  • Fig. 34 Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • Fig. 35 Speciality Pharmacy Market, 2018 - 2030 (USD Million)
  • Fig. 36 Online Pharmacy Market, 2018 - 2030 (USD Million)
  • Fig. 37 Tumor Necrosis Factor Inhibitor Drugs Market revenue, by Region
  • Fig. 38 Regional Marketplace: Key takeaways
  • Fig. 39 North America Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. country dynamics
  • Fig. 41 U.S. Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 42 Canada country dynamics
  • Fig. 43 Canada Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 44 Europe Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 UK country dynamics
  • Fig. 46 UK Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 Germany country dynamics
  • Fig. 48 Germany Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 France country dynamics
  • Fig. 50 France Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Italy country dynamics
  • Fig. 52 Italy Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 53 Spain country dynamics
  • Fig. 54 Spain Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 55 Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan country dynamics
  • Fig. 57 Japan Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 58 China country dynamics
  • Fig. 59 China Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 60 Latin America Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 61 Brazil country dynamics
  • Fig. 62 Brazil Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 63 Argentina country dynamics
  • Fig. 64 Argentina Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 65 MEA Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 66 South Africa country dynamics
  • Fig. 67 South Africa Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 68 Company categorization
  • Fig. 69 Company market position analysis
  • Fig. 70 Strategic framework